🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨 The OncoAlert RoundUp: ASCO 2025 – Day 3 Highlights 🚨 📬 Don’t miss out—subscribe now for full coverage: OncoAlert360.com or buff.ly/p0O1gZ8 Covering: 🔹 The role of exercise during adjuvant chemo in colorectal cancer (CHALLENGE) 🔹 MATTERHORN reshaping

Many thanks to VJ Oncology for featuring our study comparing immunotherapy to BRAF and MEK inhibitors for the first-line treatment of patients with BRAF V600E mutant NSCLC IASLC ESMO - Eur. Oncology Biagio Ricciuti, MD, PhD Marcelo Negrao Dana-Farber MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center vjoncology.com/video/wgsujs7x…

What about the rare stuff? Biagio Ricciuti, MD, PhD sheds light in what to do in patients with AGAs that could potentially respond to IO, such as MET, BRAF and KRAS. And it would not be Biagio without an opinion on STK11/KEAP1 co-mutations. #ASCO25

Thoughtful discussion in our #ASCO25 session on perioperative approaches in #NSCLC, including rare drivers and hard-to-treat genotypes— alongside stellar faculty Charu Aggarwal, MD, MPH, FASCO & Kaushal Parikh. ASCO Dana-Farber News Narjust Florez, MD, FASCO OncoAlert Marcelo Corassa, MD. Dana-Farber

With the best at #ASCO25 Last day and then Boston and/or Italy And our Brazilian transplant Dr. Marcelo Corassa, MD. Early stage session with a focus on target mutations

Clinical case submissions are now open for the Yin & Yang Lung Cancer Masterclass! July 11-12, 2025 in Milan, Italy <40? Oncologist, surgeon, or rad onc? Submit by June 15! Submit a case on one of the topics: 1️⃣ Multimodal Rx (resectable/LA NSCLC) 2️⃣ Adjuvant EGFR/ALK+ NSCLC 3️⃣

Don't miss the opportunity to submit a clinical case (trainees and oncologist <40 yo) for the Yin & Yang Lung Cancer Masterclass! w/stellar faculty Narjust Florez, MD, FASCO Benjamin Besse JessicaJLinMD Marina Garassino Rafeh Naqash, MD arsela prelaj & many others! Travel and

Don't miss this fantastic opportunity! Looking for you in Milan in July

Such a privilege to listen to Dr. Crinò—my first mentor—reflecting on 20 years of progress in #LungCancer treatment, from targeted therapies to immunotherapies. A masterclass in science and dedication in #Ferrara 🇮🇹. OncoAlert Dana-Farber Isabella Soares

Don’t miss the OncoAlert🚨newsletter #ASCO25 EDITION⭐️ REGISTER👉OncoAlert360.com OR buff.ly/48Xpgz0 Matteo Lambertini, MD PhD Petros Grivas Daniel Castellano Tom Powles Uromigos Janice Cowden Simon C Axel S. Merseburger Icro Meattini Erika Hamilton, MD Sara Tolaney MEDSIR

Biagio Ricciuti, MD, PhD OncoAlert Dana-Farber Isabella Soares Gonzalo Recondo Narjust Florez, MD, FASCO Alessandro Di Federico A legend.

Check out the latest 🚨OncoAlert🚨Newsletter Covering Jun 12-19, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… This week covering among others: ✅Association of HRR Alterations With Outcomes in Metastatic Hormone-Sensitive Prostate Cancer

Join us tomorrow for a free webinar where #DrDongFei from Stanford University and I will discuss the role of STK11 & KEAP1 mutations in #NSCLC. From biology to therapeutic implications. IASLC Dana-Farber News Association for Molecular Pathology Dana-Farber Register: educate.amp.org/local/catalog/…

Phase III AIM-HIGH trial (The Lancet Respiratory Medicine) by David R. Spigel, MD, FASCO et al. reports that adjuvant chemotherapy in resected stage IA–IIA non-squamous #NSCLC patients with a high-risk 14-gene score increased 2-year disease-free survival from 79% to 96%. OncoAlert thelancet.com/journals/lanre…

Don’t miss the new OncoAlert newsletter. REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… This week covering: ✅Update on FORTITUDE-101 (Industry) GEJ ✅ShortHER in #BreastCancer ✅U-BOMB Trial in Breast #Cancer ✅DADSPORT in #prostatecancer ✅KBP-2020 Study

Check out the latest 🚨OncoAlert 🚨 Round Up covering the TOP of the week July 11-17, 2025 by Gil Morgan, MD! & don’t forget to REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Highlights include: ✅TALAPRO2 in #ProstateCancer ✅Geriatric Assessment

Biagio, it will be an honor to welcome you to our institution. I'll be on vacation, but you'll be warmly welcomed! Biagio Ricciuti, MD, PhD OncoAlert #LCSM

NEOIPOWER (Lung Cancer Journal): In resectable stage II–IIIB #EGFR+ NSCLC, neoadjuvant icotinib + chemo led to an ORR of 83.3%, but MPR was just 6.7% with no pCR. Adds to growing evidence of limited pathologic response w/ TKIs in this setting.🚨 OncoAlert lungcancerjournal.info/article/S0169-…

Kicking off in <24h, the NRG Oncology Summer Symposium on ADCs promises to be epic! With over 230 registered attendees and a world class faculty, it will allow to review the terrific evolutions of this drug class across oncology fields. Still time to register! nrgoncology.org/Summer2025Mtg/…